Simultaneous exposure to Fc?R and Fc?R on monocytes and macrophages enhances antitumor activity in vivo.
Ontology highlight
ABSTRACT: Therapeutic antibodies are effective for tumor immunotherapy and exhibit prominent clinical effects. All approved antibody therapeutics utilize IgG as the molecular format. Antibody-dependent cell-mediated cytotoxicity (ADCC) is a key mechanism for tumor cell killing by antibodies. For IgG antibodies, ADCC depends on Fc?R-expressing cells, such as natural killer (NK) cells. However, in patients with a high tumor burden, antibody therapeutics may lose efficacy owing to exhaustion of Fc?R-expressing effector cells as well as the inhibitory effects of certain Fc?Rs on effector cells. To achieve more potent effector functions, we engineered an anti-CD20 antibody to contain both IgG Fc and IgA Fc domains. These engineered antibodies interacted with both IgG and IgA Fc receptors (Fc?R and Fc?R) and recruited a broader range of effector cells, including monocytes, macrophages, neutrophils, and NK cells, thereby enhancing antibody-dependent cellular phagocytosis. Using transgenic mice expressing the Fc?RI (CD89) in macrophages, we demonstrated that recombinant antibodies bearing the chimeric IgG and IgA Fc exhibited potent in vivo antitumor activity. Additionally, in a short-term peritoneal model using CD20-transfected LLC target cells, the in vivo cytotoxic activity of hybrid recombinant antibodies was mediated by macrophages with significant reduction in the absence of Fc?RI. Our findings supported targeting of Fc?RI on monocytes and macrophages for improved tumor immunotherapy.
SUBMITTER: Li B
PROVIDER: S-EPMC5503618 | biostudies-literature | 2017 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA